| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2039676 | Cell Reports | 2014 | 9 Pages |
•Cancer and normal tissues derived from iPSCs differentially depend on MYC•MYC sustains tumor-specific metabolic and chromatin changes in iPSC-derived tumors•Engineering iPSCs with dominant-negative MYC is a therapeutic fail-safe strategy
SummaryThe long-term risk of malignancy associated with stem cell therapies is a significant concern in the clinical application of this exciting technology. We report a cancer-selective strategy to enhance the safety of stem cell therapies. Briefly, using a cell engineering approach, we show that aggressive cancers derived from human or murine induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are strikingly sensitive to temporary MYC blockade. On the other hand, differentiated tissues derived from human or mouse iPSCs can readily tolerate temporary MYC inactivation. In cancer cells, endogenous MYC is required to maintain the metabolic and epigenetic functions of the embryonic and cancer-specific pyruvate kinase M2 isoform (PKM2). In summary, our results implicate PKM2 in cancer’s increased MYC dependence and indicate dominant MYC inhibition as a cancer-selective fail-safe for stem cell therapies.
Graphical AbstractFigure optionsDownload full-size imageDownload as PowerPoint slide
